Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Name

Click to order products ascending

Display 15 Products per page

Volasertib
Read More
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.
April 22, 2014
Find out more
Vonvendi
Read More
Vonvendi (Shire) became the first recombinant von Willebrand factor (rVWF) therapy approved in the US in December 2015.
May 4, 2018
Find out more
Vosevi
Read More
Vosevi ([sofosbuvir + velpatasvir + voxilaprevir]) is Gilead’s third-generation, pan-genotypic, interferon-free regimen. The fixed-dose combination contains the hepatitis C virus nucleotide NS5B inhibitor sofosbuvir, a second-generation NS5A inhibitor (velpatasvir), and the company’s NS3 protease inhibitor (voxilaprevir).
November 6, 2017
Find out more
Votrient
Read More
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
March 6, 2019
Find out more
Vraylar
Read More
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.
March 29, 2018
Find out more
Vyxeos
Read More
Vyxeos (cytarabine/daunorubicin; Jazz Pharmaceuticals) is a liposomal formulation of a 5:1 molar ratio of cytarabine and daunorubicin – chemotherapy drugs which are currently administered as two separate intravenous injections as part of the 7+3 regimen for the treatment of acute myeloid leukemia.Vyxeos (cytarabine/daunorubicin; Jazz Pharmaceuticals) is a liposomal formulation of a 5:1 molar ratio of cytarabine and daunorubicin – chemotherapy drugs which are currently administered as two separate intravenous injections as part of the 7+3 regimen for the treatment of acute myeloid leukemia.
July 6, 2017
Find out more
Waylivra
Read More
Waylivra (volanesorsen; Ionis Pharmaceuticals) is an antisense drug that inhibits the translation and production of ApoC-III.
November 20, 2019
Find out more
Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – Spain

$599.00

A Spain-based KOL opines about the most used agents in wet AMD with particular emphasis on the effect of cost and safety in making prescribing decisions. During the discussion, the KOL gives a glimpse of what the future might hold in terms of newer agents and combination therapy. The KOL also speaks about novel modes of administration and the impact of these on the current market.
September 29, 2022
Find out more
Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – US #1

$599.00

A US-based KOL opines about various biologics currently in use in clinical practice. During the discussion, the KOL speaks about their views on the safety and durability of currently approved agents, the newer modes of administration, and the role of each approved agent in the treatment armamentarium.
September 29, 2022
Find out more
Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – US #2

$599.00

A US-based KOL speaks on the current market trends and how cost, durability, and efficacy play a key role in prescribing decisions. The KOL also talks about newer therapies that might overthrow current market leaders, and the future of newer biologics in the market.
September 29, 2022
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more
Women’s Health: Osteoporosis Diagnostic Products

$3,750.00

This report provides analyses of products, markets, and competitors in the global market for osteoporosis diagnostic products. This market, as covered by the scope of this report, includes products that are used to diagnose osteoporosis, including bone densitometry systems and bone remodeling biochemical marker tests.
December 13, 2016
Find out more
Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

$3,750.00

This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
September 2, 2013
Find out more
Women’s Health: U.S. Markets for Female Urinary Incontinence Therapies

$3,750.00

This report focuses on minimally invasive therapy systems and medications designed for the treatment of female UI, including OAB pharmaceutical or drug treatments, injectable urethral bulking agents, and urethral sling systems, of which the OAB drug treatments market contributes the vast majority of revenues.
September 22, 2016
Find out more
Women’s Health: U.S. Markets for Reproductive Management Products

$3,750.00

This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.

September 2, 2013
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *